Guggenheim raised the firm’s price target on Cybin (CYBN) to $48 from $39 and keeps a Buy rating on the shares. Noting that the company’s Phase 3 program for CYB003 in adjunctive MDD is advancing as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results